What's Happening?
Roche has released new Phase III data for its experimental KRAS G12C inhibitor, divarasib, which shows improved efficacy over existing therapies from Amgen and Bristol Myers Squibb. The Krascendo 1 study compared divarasib directly with Amgen's Lumakras
and BMS's Krazati in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Divarasib demonstrated statistically significant improvements in progression-free survival and overall survival, suggesting it could become a new standard of care for this patient population. The study's results will support regulatory filings and further clinical development.
Why It's Important?
The success of divarasib in the Krascendo 1 trial is crucial as it addresses a significant unmet need in the treatment of KRAS G12C-mutant NSCLC, a challenging cancer subtype with limited effective therapies. The KRAS G12C mutation is a common oncogene mutation in NSCLC, and current treatments have struggled with issues like drug resistance and narrow patient populations. Divarasib's superior performance could lead to better patient outcomes and potentially reshape the treatment landscape for this genetic subtype, offering hope for improved survival and quality of life.
What's Next?
Roche plans to use the trial results to seek regulatory approval for divarasib, aiming to make it available to patients as soon as possible. The company is also conducting additional trials, including Krascendo 2 and Krascendo 3, to explore divarasib's use in combination with other therapies and in different stages of lung cancer. These efforts are part of Roche's broader strategy to expand the drug's application and enhance its therapeutic impact across various cancer settings.
